Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers
November 9th 2023Domvanalimab plus zimberelimab with chemotherapy demonstrated a positive overall response rate and 6-month progression free survival rate for patients with upper gastrointestinal cancers.
Read More